Last reviewed · How we verify

bevacizumab, Paclitaxel — Competitive Intelligence Brief

bevacizumab, Paclitaxel (bevacizumab, Paclitaxel) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiangiogenic agent, Microtubule inhibitor. Area: Oncology.

phase 3 Antiangiogenic agent, Microtubule inhibitor VEGF-A, Tubulin Oncology Biologic Live · refreshed every 30 min

Target snapshot

bevacizumab, Paclitaxel (bevacizumab, Paclitaxel) — Swiss Cancer Institute. Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while paclitaxel is a microtubule inhibitor that blocks cell division.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
bevacizumab, Paclitaxel TARGET bevacizumab, Paclitaxel Swiss Cancer Institute phase 3 Antiangiogenic agent, Microtubule inhibitor VEGF-A, Tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiangiogenic agent, Microtubule inhibitor class)

  1. Swiss Cancer Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bevacizumab, Paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/bevacizumab-paclitaxel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: